Marin Richeson

In the previous five posts in this series, I’ve taken you on a little journey designed to help you improve your relationship with your clinical sites, thereby boosting their performance and reducing your costs. In this, the final post in the series, I’ll summarize the key takeaways and offer up some additional resources to help […]

Imagine with me: An investigator running a site in one of your studies logs in to see an overview of his payment history. Something seems off, so he begins to review each payment in detail, and comes across what he believes to be the source of the problem – the withholding for his first payment […]

If you haven’t read the previous posts in this series, be forewarned that this week’s post might be a little hard to follow, as it assumes you have all of the context from the series to-date. Still, I encourage you to dive in, and I’ll do my best to connect all of the dots for […]

In the previous posts in this series, I’ve explained why you should consider clinical sites as your “customers,” and what customer experience (CX) methodology is and how it’s used. In this post, I’ll explain how the methodology applies to clinical sites and how the insights it provides can help improve site relationships. With the notion […]

In the previous posts in this series on improving relationships with clinical sites, I discussed why it’s beneficial to think of your clinical sites as your customers so that you can use customer experience (CX) methodology to improve those relationships. In this post, I’ll explain what CX methodology is and why it matters. At its […]

Earlier this year, Duke University and the United States Food and Drug Administration (FDA) published a jointly conducted study focused on principal investigator (PI) retention. After surveying 201 PIs, they confirmed the industry’s suspicion that PI turnover is a serious issue: 54.2% of respondents reported that they completed a single clinical trial and then stopped. […]

Last time, I published a post that posed the question: why are prescription drugs in the U.S. so expensive? Today’s post is the first in a brief series that will attempt to provide an answer by looking each stage of the FDA drug approval process, starting with preclinical. Below are the key components of the […]

In the previous post in this series, I discussed the process you can use to determine whether a particular IT system is regulated. That post described the first part of a four-part approach to assessing and mitigating risk with regulated IT systems. Today’s post will cover the second part – what to do once you […]

Clinical trials are the biggest expense in the drug development process, and there are myriad systems out there designed to reduce operational costs. In fact, Perficient implements, integrates, and hosts several of them. But, what we are seeing now in the life sciences industry is a growing awareness of front-line operations; that is, an interest […]

The pharmaceutical and biotechnology industry is an incredibly rewarding place to work. We get to help patients feel better, more effectively manage their conditions, cure their diseases, and even prevent them from getting sick all together. But the life sciences industry is not without its challenges. According to a recent Pharmaceutical Research and Manufacturers of […]

A couple weeks back, I launched a brief blog series about assessing and mitigating risk with regulated IT systems. This week’s post will cover the first part in a four-part approach you can use to do just that: assess and mitigate risk. Part One: System Regulated Status The first step is to determine whether a […]

In the life sciences industry, many of the software systems we use must comply with federal regulations. The purpose of these regulations, such as U.S. FDA 21 CFR Part 11, is to ensure that the data being housed and produced by these software systems is accurate and trustworthy. When the FDA first introduced 21 CFR […]